CA2177179C - Antagonists to chaperonin 10 - Google Patents
Antagonists to chaperonin 10 Download PDFInfo
- Publication number
- CA2177179C CA2177179C CA002177179A CA2177179A CA2177179C CA 2177179 C CA2177179 C CA 2177179C CA 002177179 A CA002177179 A CA 002177179A CA 2177179 A CA2177179 A CA 2177179A CA 2177179 C CA2177179 C CA 2177179C
- Authority
- CA
- Canada
- Prior art keywords
- epf
- cpnl0
- cells
- antibodies
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000005557 antagonist Substances 0.000 title abstract description 10
- 102100024341 10 kDa heat shock protein, mitochondrial Human genes 0.000 title description 92
- 108010059013 Chaperonin 10 Proteins 0.000 title description 6
- 230000010261 cell growth Effects 0.000 claims abstract description 9
- 230000002708 enhancing effect Effects 0.000 claims abstract description 4
- 230000001900 immune effect Effects 0.000 claims abstract description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 59
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 37
- 230000035935 pregnancy Effects 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 19
- 230000012010 growth Effects 0.000 claims description 15
- 210000004881 tumor cell Anatomy 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 238000007792 addition Methods 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 5
- 230000001629 suppression Effects 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 20
- 238000003556 assay Methods 0.000 abstract description 4
- 101150006844 groES gene Proteins 0.000 abstract 6
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 108010046025 early pregnancy factor Proteins 0.000 description 86
- 230000000694 effects Effects 0.000 description 24
- 210000001772 blood platelet Anatomy 0.000 description 18
- 239000012634 fragment Substances 0.000 description 18
- 239000000499 gel Substances 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 18
- 229940092253 ovalbumin Drugs 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 13
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 101100166957 Anabaena sp. (strain L31) groEL2 gene Proteins 0.000 description 12
- 101100439396 Synechococcus sp. (strain ATCC 27144 / PCC 6301 / SAUG 1402/1) groEL1 gene Proteins 0.000 description 12
- 101150077981 groEL gene Proteins 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 108010058846 Ovalbumin Proteins 0.000 description 9
- 238000004166 bioassay Methods 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000002788 anti-peptide Effects 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 6
- 229920002684 Sepharose Polymers 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 229940104230 thymidine Drugs 0.000 description 6
- 101710104159 Chaperonin GroEL Proteins 0.000 description 5
- 101710108115 Chaperonin GroEL, chloroplastic Proteins 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 229940090044 injection Drugs 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 201000008808 Fibrosarcoma Diseases 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 210000003293 antilymphocyte serum Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000001382 Experimental Melanoma Diseases 0.000 description 3
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 3
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 3
- 102000005431 Molecular Chaperones Human genes 0.000 description 3
- 108010006519 Molecular Chaperones Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000003305 autocrine Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000001143 conditioned effect Effects 0.000 description 3
- 210000004246 corpus luteum Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000002512 suppressor factor Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108050001186 Chaperonin Cpn60 Proteins 0.000 description 2
- 102000052603 Chaperonins Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 210000004898 n-terminal fragment Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000010118 platelet activation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- WMYLYYNMCFINGV-CKCBUVOCSA-N (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O.OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O WMYLYYNMCFINGV-CKCBUVOCSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- CFBILACNYSPRPM-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]acetic acid Chemical compound OCC(N)(CO)CO.OCC(CO)(CO)NCC(O)=O CFBILACNYSPRPM-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 235000013175 Crataegus laevigata Nutrition 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 108091060211 Expressed sequence tag Proteins 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920006063 Lamide® Polymers 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 101150049281 PRM1 gene Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 108010030544 Peptidyl-Lys metalloendopeptidase Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 101000946278 Rattus norvegicus 10 kDa heat shock protein, mitochondrial Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 101710117064 Trimethylamine corrinoid protein 1 Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000002311 liver mitochondria Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000005648 named reaction Methods 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- -1 o-phenvlene diamine Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012753 partial hepatectomy Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pregnancy & Childbirth (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPM2705 | 1993-11-30 | ||
| AUPM270593 | 1993-11-30 | ||
| AUPM8234A AUPM823494A0 (en) | 1994-09-16 | 1994-09-16 | Diagnostic and therapeutic uses of chaperonin 10 |
| AUPM8234 | 1994-09-16 | ||
| PCT/AU1994/000742 WO1995015339A1 (en) | 1993-11-30 | 1994-11-30 | Antagonists to chaperonin 10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2177179A1 CA2177179A1 (en) | 1995-06-08 |
| CA2177179C true CA2177179C (en) | 2006-10-17 |
Family
ID=25644587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002177179A Expired - Fee Related CA2177179C (en) | 1993-11-30 | 1994-11-30 | Antagonists to chaperonin 10 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US6113899A (enExample) |
| EP (2) | EP0733071A4 (enExample) |
| JP (3) | JP3987104B2 (enExample) |
| AT (1) | ATE282634T1 (enExample) |
| AU (2) | AU684578B2 (enExample) |
| CA (1) | CA2177179C (enExample) |
| DE (1) | DE69434137T2 (enExample) |
| ES (1) | ES2233938T3 (enExample) |
| NZ (2) | NZ276670A (enExample) |
| PT (1) | PT731811E (enExample) |
| WO (2) | WO1995015338A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE282634T1 (de) * | 1993-11-30 | 2004-12-15 | Univ Queensland | Chaperonin 10 |
| WO1999002989A1 (en) * | 1997-07-10 | 1999-01-21 | Medical Research Council | Chaperone fragments |
| US6007821A (en) * | 1997-10-16 | 1999-12-28 | Fordham University | Method and compositions for the treatment of autoimmune disease using heat shock proteins |
| US6475490B1 (en) | 1998-10-19 | 2002-11-05 | Fordham University | Compositions and methods for promoting tissue repair using heat shock proteins |
| AUPP823999A0 (en) * | 1999-01-20 | 1999-02-11 | University Of Queensland, The | A treatment |
| GB0028122D0 (en) * | 2000-11-17 | 2001-01-03 | St Georges Entpr Ltd | Method |
| AU2002317013B2 (en) * | 2001-06-27 | 2007-11-01 | Janssen Pharmaceutica N.V. | EPF receptor assays, compounds and therapeutic compositions |
| AU2002952492A0 (en) | 2002-11-06 | 2002-11-21 | Cbio Limited | Chaperonin 10 immunosuppression |
| GB0226105D0 (en) * | 2002-11-08 | 2002-12-18 | St Georges S Entpr Ltd | Pain relief agents |
| WO2005067959A1 (en) * | 2004-01-16 | 2005-07-28 | Cbio Limited | Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion |
| BRPI0615284A2 (pt) | 2005-08-31 | 2011-05-17 | Cbio Ltd | chaperonina 10 modificada |
| EP1951282A4 (en) * | 2005-10-20 | 2009-09-02 | Cbio Ltd | TREATMENT OF HYPERSENSITIVITY |
| AU2006303826B2 (en) * | 2005-10-20 | 2012-07-19 | Cbio Limited | Treatment of hypersensitivity |
| CN101443032A (zh) | 2006-03-02 | 2009-05-27 | 悉生物有限公司 | 通过调节抗原呈递细胞的功能调节免疫反应 |
| NZ588467A (en) | 2008-04-11 | 2012-11-30 | Cbio Ltd | Modified chaperonin 10 (CPN10) polypeptides and pattern recognition receptor (PRR) signalling |
| NZ599666A (en) * | 2009-10-09 | 2014-11-28 | Cbio Ltd | Chaperonin 10 variants |
| US20110243921A1 (en) * | 2010-03-30 | 2011-10-06 | Cbio Limited | Prevention and treatment of cutaneous lupus erythematosus |
| KR101776013B1 (ko) * | 2017-05-26 | 2017-09-07 | (주)넥스젠바이오텍 | 항산화 활성 및 피부 세포 증식 효과가 증가한 열 충격 단백질 10과 브라제인 단백질의 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1986005498A1 (en) * | 1985-03-12 | 1986-09-25 | University Of Queensland | Method for detecting early pregnancy factor (epf) in mammals, purifying epf and method for producing a monoclonal antibody |
| AU599021B2 (en) * | 1985-03-12 | 1990-07-12 | University Of Queensland, The | Method for detecting early pregnancy factor (epf) in mammals,purifying epf and method for producing a monoclonal antibody |
| WO1988004779A1 (en) * | 1986-12-22 | 1988-06-30 | University Of Queensland | Method of treatment of mammals using antibodies to early pregnancy factor (epf) |
| AU1086988A (en) * | 1986-12-22 | 1988-07-15 | University Of Queensland, The | Method of treatment of mammals using antibodies to early pregnancy factor (epf) |
| ATE282634T1 (de) * | 1993-11-30 | 2004-12-15 | Univ Queensland | Chaperonin 10 |
-
1994
- 1994-11-30 AT AT95902003T patent/ATE282634T1/de not_active IP Right Cessation
- 1994-11-30 DE DE69434137T patent/DE69434137T2/de not_active Expired - Lifetime
- 1994-11-30 AU AU11036/95A patent/AU684578B2/en not_active Ceased
- 1994-11-30 ES ES95902003T patent/ES2233938T3/es not_active Expired - Lifetime
- 1994-11-30 WO PCT/AU1994/000740 patent/WO1995015338A1/en not_active Ceased
- 1994-11-30 AU AU11034/95A patent/AU684577B2/en not_active Ceased
- 1994-11-30 JP JP51529695A patent/JP3987104B2/ja not_active Expired - Fee Related
- 1994-11-30 PT PT95902003T patent/PT731811E/pt unknown
- 1994-11-30 EP EP95902005A patent/EP0733071A4/en not_active Withdrawn
- 1994-11-30 NZ NZ276670A patent/NZ276670A/en not_active IP Right Cessation
- 1994-11-30 NZ NZ276672A patent/NZ276672A/en not_active IP Right Cessation
- 1994-11-30 CA CA002177179A patent/CA2177179C/en not_active Expired - Fee Related
- 1994-11-30 WO PCT/AU1994/000742 patent/WO1995015339A1/en not_active Ceased
- 1994-11-30 JP JP51529495A patent/JP3545408B2/ja not_active Expired - Fee Related
- 1994-11-30 EP EP95902003A patent/EP0731811B1/en not_active Expired - Lifetime
-
1996
- 1996-05-29 US US08/654,618 patent/US6113899A/en not_active Expired - Lifetime
-
1999
- 1999-02-23 US US09/255,703 patent/US6417334B1/en not_active Expired - Fee Related
-
2002
- 2002-05-21 US US10/151,006 patent/US7358329B2/en not_active Expired - Fee Related
-
2003
- 2003-09-11 JP JP2003319869A patent/JP3986481B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69434137T2 (de) | 2005-12-01 |
| EP0733071A4 (en) | 1997-02-26 |
| PT731811E (pt) | 2005-04-29 |
| CA2177179A1 (en) | 1995-06-08 |
| WO1995015338A1 (en) | 1995-06-08 |
| JPH09505811A (ja) | 1997-06-10 |
| JP2004067698A (ja) | 2004-03-04 |
| AU1103695A (en) | 1995-06-19 |
| US7358329B2 (en) | 2008-04-15 |
| JP3986481B2 (ja) | 2007-10-03 |
| JP3545408B2 (ja) | 2004-07-21 |
| NZ276670A (en) | 1998-01-26 |
| US6113899A (en) | 2000-09-05 |
| AU684578B2 (en) | 1997-12-18 |
| DE69434137D1 (en) | 2004-12-23 |
| ES2233938T3 (es) | 2005-06-16 |
| US20030175280A1 (en) | 2003-09-18 |
| AU684577B2 (en) | 1997-12-18 |
| AU1103495A (en) | 1995-06-19 |
| EP0731811A1 (en) | 1996-09-18 |
| EP0733071A1 (en) | 1996-09-25 |
| JPH09506431A (ja) | 1997-06-24 |
| ATE282634T1 (de) | 2004-12-15 |
| US6417334B1 (en) | 2002-07-09 |
| JP3987104B2 (ja) | 2007-10-03 |
| EP0731811A4 (en) | 2003-05-28 |
| EP0731811B1 (en) | 2004-11-17 |
| WO1995015339A1 (en) | 1995-06-08 |
| NZ276672A (en) | 1998-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2177179C (en) | Antagonists to chaperonin 10 | |
| Murgita et al. | Suppression of the immune response by alpha-fetoprotein on the primary and secondary antibody response. | |
| Kummer et al. | Production and characterization of monoclonal antibodies raised against recombinant human granzymes A and B and showing cross reactions with the natural proteins | |
| JPH03197499A (ja) | 腫瘍壊死因子結合蛋白 | |
| JPH07502496A (ja) | Ｃｄ２／ｌｆａ−３相互作用の阻害剤を用いる抗原提示細胞による皮膚障害の予防または治療の方法 | |
| Husby et al. | Amyloid fibril protein subunit,‘protein AS’: distribution in tissue and serum in different clinical types of amyloidosis including that associated with myelomatosis and Waldenström's macroglobulinaemia | |
| Cavanagh | Production in vitro of mouse early pregnancy factor and purification to homogeneity | |
| IBRAHIM et al. | Reproductive tract secretions and bull spermatozoa contain different clusterin isoforms that cluster cells and inhibit complement‐induced cytolysis | |
| Goodfellow et al. | Monoclonal antibodies reacting with murine teratocarcinoma cells. | |
| US6117421A (en) | Method for promoting cell growth and immunosuppression using chaperonin | |
| JPH04505614A (ja) | タンパク質複合体 | |
| US5723582A (en) | Antigen-specific human glycosylation inhibiting factor | |
| WO1994015637A2 (en) | Prevention of suppression of immune defense against cancer caused by the cancer-associated scm-recognition peptides | |
| Kownatzki | Studies on a fragment of human IgM macroglobulins related to “J chain” | |
| Sivapurapu et al. | Efficacy of antibodies against Escherichia coli expressed chimeric recombinant protein encompassing multiple epitopes of zona pellucida glycoproteins to inhibit in vitro human sperm–egg binding | |
| Pleau et al. | [19] Thymulin | |
| Tokuyama et al. | Separation and comparison of human TL-like antigens and HLA (A, B, C) antigens expressed on cultured T cells | |
| Hongo et al. | Immunochemical characterization of rat testicular asparagine synthetase | |
| US6387875B1 (en) | Method of use for murine leukaemia inhibitory factor-binding protein (mLBP) | |
| JPS61100598A (ja) | 抗原性ペプチド化合物 | |
| WO1991015236A1 (en) | Treatment of autoimmune diseases | |
| JPH08196272A (ja) | ハイブリドーマ２９ｄ３８ | |
| JPH08182497A (ja) | ハイブリドーマ２７ｄ５７ | |
| Pizzonia | Cell biology of the Tamm-Horsfall glycoprotein | |
| Morrow | The structure-function relationship of glucose-dependent insulinotropic polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20131202 |